Understanding the relationship between hyperglycemia, BMI-1, and PHLPP functions may contribute in the future to the development of therapeutic approaches that will be better adapted to the molecular context and the specificity of endometrial cancers and be more effective in the case of metabolic disease co-existence. This evidence concerns the gene BMI1 and metabolic disease.